Bvf Inc Protagonist Therapeutics, Inc Call Options Transaction History
Bvf Inc
- $2.54 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PTGX
# of Institutions
297Shares Held
67.4MCall Options Held
290KPut Options Held
318K-
Farallon Capital Management LLC San Francisco, CA6.17MShares$400 Million1.53% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$373 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$373 Million4.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.36MShares$283 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.25MShares$210 Million6.36% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $3.18B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...